Interestingly, T7E1 assays using sgIQ 1.1 loaded C9HuH-7exo and HN3LC9-293exo showed 20.1% and 17.6% indels of gene editing respectively and proved that via HN3-GPC3 mediated target specificity HN3LC9-293exo also could deliver the plasmid DNA into the recipient cancer cells as same as the tumor-derived C9HuH-7exo and thus act as effective natural carriers for CRISPR/Cas9 delivery platform. Here, GPC3 is linked to cancer.